Submitted by Anonymous (not verified) on 22 September 2023 - 14:53
Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 09/12/2021, Revision: 3, Status: Authorised
Source: